Ranolazine

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diastolic Heart Failure

Conditions

Diastolic Heart Failure

Trial Timeline

Apr 1, 2010 → Feb 1, 2011

NCT ID

NCT01163734

About Ranolazine

Ranolazine is a phase 2 stage product being developed by Gilead Sciences for Diastolic Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT01163734. Target conditions include Diastolic Heart Failure.

What happened to similar drugs?

3 of 4 similar drugs in Diastolic Heart Failure were approved

Approved (3) Terminated (0) Active (1)

✅regadenosonAstellas PharmaApproved

✅ValsartanNovartisApproved

✅valsartanNovartisApproved

🔄Sildenafil + PlaceboPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02360397	Phase 2	Completed	Dec 1, 2014	Feb 23, 2018	Ventricular Premature Complexes
NCT02251457	Phase 1	Completed	Aug 1, 2014	Dec 18, 2017	Myotonia Congenita
NCT01721967	Approved	Completed	Nov 1, 2012	May 1, 2016	Hypertrophic Cardiomyopathy
NCT01705509	Pre-clinical	Terminated	Sep 1, 2012	Mar 31, 2017	Cardiomyopathy
NCT01804543	Pre-clinical	UNKNOWN	Jun 1, 2012	Dec 1, 2014	Angina
NCT01435174	Approved	Completed	Oct 1, 2011	Mar 1, 2013	End-stage Renal Disease
NCT02133352	Approved	Completed	Jul 1, 2011	May 1, 2014	Pulmonary Hypertension
NCT01334203	Approved	Withdrawn	May 1, 2011	Dec 1, 2012	Angina Pectoris
NCT01304095	Approved	UNKNOWN	Jan 1, 2011	Nov 1, 2013	Coronary Artery Disease
NCT01174173	Phase 3	Completed	Jun 1, 2010	Oct 1, 2014	Angina
NCT01163734	Phase 2	Completed	Apr 1, 2010	Feb 1, 2011	Diastolic Heart Failure
NCT00644332	Approved	Completed	Nov 1, 2007	Jan 1, 2011	Chronic Angina
NCT00091429	Phase 3	Completed	Aug 1, 2004	Feb 1, 2005	Angina

Competing Products

6 competing products in Diastolic Heart Failure

See all competitors

Product	Company	Stage	Hype Score
regadenoson	Astellas Pharma	Approved	43
Dapagliflozin + Placebo	AstraZeneca	Phase 2	31
Valsartan	Novartis	Approved	43
valsartan	Novartis	Approved	43
Sitexsentin sodium + Placebo	Pfizer	Phase 2	35
Sildenafil + Placebo	Pfizer	Phase 3	40